Fifteen medical devices are potentially eligible for EU-level Joint Clinical Assessment in 2026

In January 2026, the HTA Coordination Group (HTACG) published the report on Emerging Health Technologies identified in 2025 within the framework of the EU Regulation on Health Technology Assessment (HTAR). Such reports aim to inform stakeholders about identified technologies (medicines, medical devices, in-vitro diagnostics) that may be eligible for Joint Clinical Assessments (JCAs) from 2026.

The 2025 report identified 15 medical devices grouped into generic categories, without naming specific products. The categories are as follows:

• Implantable prostatic and osteosynthesis devices (n=8);
• Active-implantable devices (n=4);
• Cardiocirculatory system devices (n=2);
• Dental, ophthalmologic, and ENT devices (n=1).

In-vitro diagnostics (IVDs) were not included in the 2025 report due to data limitations. 

Identification of Emerging Health Technologies potentially eligible for JCA forms part of the broader selection process:

• The European Medicines Agency (EMA) provides scientific advice through its expert panels on eligible medical devices and IVDs. Anonymized, aggregated, and non-confidential information is reported by the subgroup for the Identification of Emerging Health Technologies;
• The JCA subgroup of the HTA Coordination Group evaluates these technologies against predefined criteria and issues provisional recommendations on selection for JCA;
• The HTA Coordination Group reviews the provisional selection and adopts final recommendations;
• Commission implementing decisions are then formalized selection technologies for JCA based on the HTA Coordination Group’s recommendations.

Approximately five JCAs for medical devices are expected to be launched in 2026. 

See full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.